TP53 and breast carcinoma: Additionally, SLIdR predicted several significant SL partners specific to TP53, including HMGA1, RAB14, and RAC1 in osteosarcoma, renal, and breast cancers, respectively (Fig. 3b; Supplementary Data 2).